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Congenital lacticacidemia caused by lipoamide 
dehydrogenase deficiency with favorable outcome
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A 5-year-old boy had recurrent vomiting and lethargy with lacticacidemia and 
ketoacidemia since birth. Lipoamide dehydrogenase deficiency was found in 
muscle and fibroblasts. Therapy with sodium dichioroacetate, thiamine, and 
carnitine was associated with reduction of the severity and frequency of the 
decompensation episodes and near normal plasma lactate levels. At 5 years 
of age, the patient has normal cognitive function and moderate motor impair­
ment. (J Pediatr 1995;126:72-4)
Inborn errors of metabolism associated with combined lac­
ticacidemia and ketoacidemia usually cause life-threaten­
ing metabolic decompensation in infancy. In many cases the 
primary enzymatic defect can be localized to the pyruvate 
dehydrogenase complex or to the mitochondrial respiratory 
chain. The most common defect in the PDHC resides in its 
El subunit; deficiency of the E3 subunit (lipoamide dehy­
drogenase) has been reported in only a few patients, 1"5 
whose clinical course was characterized by progressive 
neurologic deterioration; most died during early childhood.
We describe a 5-year-old boy with LAD deficiency who 
has been treated for the past 3 years with sodium dichioro­
acetate, thiamine, and carnitine. His cognitive functions 
were age appropriate, but his motor development was mod­
erately impaired.
C A SE R EPO R T
A 7-month-old boy was admitted because of refusal to eat and 
recurrent vomiting for 24 hours. He was the third child of noncon- 
sanguineous Ashkenazi-Jewish parents. Two older sisters were 
healthy. He was born in another hospital after an uneventful preg­
nancy and delivery; birth weight was 4000 gm. He had an episode 
of tachypnea and vomiting 12 hours after birth, with a plasma lac­
tate concentration of 7.0 mmol/L (normal, <2.4 mmol/L) and to-
*
lal ketone bodies of 1,27 mmol/L (normal, <0.24 mmol/L).
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Thereafter he was hospitalized every 6 to 8 weeks for loss of appe­
tite, recurrent vomiting, and hyperlactatemia (Figure). Thiamine, 
riboflavin, coenzyme Q, and biotin were given for a suspected mi­
tochondrial disorder. None of these agents had reduced the fre­
quency of the attacks.
Physical examination revealed tachycardia, tachypnea, pallor, 
hepatomegaly, and muscle hypotonia. Blood pH was 7.15, partial 
pressure of carbon dioxide 19 mm Hg, plasma lactate concentra­
tion 9.8 mmol/L, and total ketone bodies 6,61 mmol/L. Plasma 
carnitine concentration was 21.8 ¿tmol/L (normal, 30 /¿mol/L),
DCA Sodium dichioroacetate
LAD Lipoamide dehydrogenase
NADH Nicotinamide adenine dinucleotide (reduced
form)
PDHC Pyruvate dehydrogenase complex
Serum aspartate aminotransferase activity was 10,000 IU /L  (nor­
mal, <  50 IU /L), alanine aminotransferase 12,000 IU /L  (normal, 
< 56 IU /L), and prothrombin time 40% of the control value. Cre­
atine kinase activity was normal. Plasma amino acid values were 
normal except for an increased alanine concentration. Cerebrospi­
nal fluid lactate concentration was 1.4 mmol/L. Abdominal ultra­
sonography revealed liver and kidneys of normal size. Findings of 
echocardiography and cranial computed tomography were normal. 
The patient gradually improved after intravenous administration of 
glucose and Na bicarbonate solution. However, when he was clin­
ically well, plasma lactate concentration and ketone bodies re­
mained elevated. Open muscle biopsy was performed with the pa­
tient under general anesthesia, and muscle tissue was obtained from 
the right quadriceps. Electron microscopic findings, including mi­
tochondrial size and shape, were normal. The main portion was 
immediately frozen at —70° C for enzymatic analysis.
Similar episodes during the following 2 months were accompa-
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Figure. Lactate concentration (in millimoles per liter) as a function of year of life. Therapy was started at 9 months of 
age. The increased lactate concentrations after 4 years of age were associated with the discontinuation of DCA admin­
istration.
nied by moderate neurologic deterioration with severe generalized 
hypotonia and inability to sit unsupported. A therapeutic trial with 
DCA, carnitine, thiamine, lipoic acid, Na succinate, and restriction 
of branched-chain amino acids was initiated. This regimen was as­
sociated with normalization of plasma lactate values, but plasma 
ketones remained elevated.
Since 2 years of age the patient had been treated with DCA, thi­
amine, and carnitine. In addition to his regular oral intake, supple­
mentary nasogastric feeding was maintained because of periods of 
anorexia. During the second year he had only four episodes of re­
current vomiting in association with elevated liver transaminase 
values, moderate hyperketonemia, and nearly normal plasma lac­
tate levels. No such episodes were noted thereafter. Repeated at­
tempts since 4 years of age to reduce DCA dosage to less than 25 
to 30 m g/kg every 12 hours resulted in hyperlactatemia (Figure). 
At 5 years, the patient’s weight was at the 50th percentile, length 
at the 75th percentile, and head circumference at the 50th percen­
tile. The patient had hepatomegaly and general muscular hypoto­
nia. He walked freely on a broad base, comprehension was age ap­
propriate, and he spoke fluently, Cranial computed tomography, 
electroencephalography, electromyography, nerve conduction ve­
locity, visual evoked potentials, electroretinography, electrocardio­
graphy, echocardiography, and abdominal ultrasonography, per­
formed every year, showed results within the normal range.
M E T H O D S
Plasma lactate levels were determined in 15 samples be­
fore therapy was started and in 66 samples during therapy. 
Urinary organic acids were identified with a Hewlett-Pack­
ard 5970 mass selective detector as previously described.6
In muscle homogenate, the activities of rotenone-sensi- 
tive NADH:ubiquinone oxidoreductase, antimycine-sensi- 
tive succinate:cytochrome c oxidoreductase, cytochrome c 
oxidase, citrate synthase, PDHC, the El subunit, LAD, and
a-ketoglutarate dehydrogenase complex were determined 
according to previously described methods.7,8 In sonicated 
fibroblasts, the activities of PDHC, LAD, and a-ketoglut­
arate dehydrogenase complex were determined as previ­
ously described.9,10
Dichloroacetic acid, succinic acid (Sigma Chemical Co., 
St. Louis, Mo.), and lipoic acid (Astra Pharma, Frankfurt, 
Germany) were converted to their sodium salt (pH 5.0 to 
7.0) with sodium hydroxide. These drugs were administered 
orally after Ministry of Health approval and informed pa­
rental consent.
R E S U L T S
Mean plasma lactate concentrations were significantly 
lower after therapy (2.4 ±  0.9 mmol/L) than before (4.8 ±  
2.1 mmol/L) (Figure).
On admission, urinary organic acid.analysis revealed el­
evated lactic, /3-hydroxybutyric, a-ketoglutaric, and a-ke- 
toadipic acid levels (11.63, 1.47, 4.14, and 0.27 mol/mol 
creatinine, respectively). After introduction of therapy, 
only mild organic aciduria was found (0.18, 0.04, 0.94, and
0.15 mol/mol creatinine, respectively).
In muscle, PDHC activity was 0.51 m U/gm  wet weight, 
LAD 11.0 mU/gm, and a-ketoglutarate dehydrogenase 
complex0.54 mU/gm (control values, 5.0 ±  1.8,101 ± 2 6 ,  
and 3.8 ±  1.2 m U/gm , respectively). The activities of the 
other enzymes were within the normal range. In fibroblasts, 
the activity of PDHC was 14,1 nmol/hr per milligram of 
protein, LAD 235 nmol/hr per milligram, and a-ketoglut- 
arate dehydrogenase complex 14.4 nmo/hr per milligram 
(control values, 23.4 ±  3.0, 2334 ±  288, and 22,2 ±  4.8 
nmol/hr per milligram of protein, respectively).
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DISCUSSION
Lipoamide dehydrogenase is one of the three catalytic 
proteins of the PDHC that converts pyruvate to acetyl-co- 
enzyme A. LAD is also a component of two other a-keto 
acid dehydrogenase complexes: a-ketoglutarate dehy­
drogenase complex and branched-chain keto acid dehy­
drogenase complex. Thus a deficiency of LAD results in 
extensive metabolic disturbances, including lacticacide­
mia, Krebs cycle dysfunction with decreased NADH pro­
duction, and impaired degradation of branched-chain amino 
acids.
Five patients with LAD deficiency have been reported.1'5 
All had severe neurologic damage early in life. Their clin­
ical course was characterized by frequent episodes of met­
abolic decompensation and slow neurologic deterioration. 
Therapy with thiamine, glutamine, biotin, lipoic acid, 
restriction of branched-chain amino acids, and a low- 
carbohydrate, high-fat diet did not seem to influence their 
neurologic course; only lipoic acid was reported to be of 
some biochemical benefit. Three patients died at 7 to 21 
months of age, and two remained severely retarded.
For the past 3 years our patient has been treated with 
DCA, thiamine, and carnitine. During this period the 
frequency and severity of his decompensation episodes 
decreased markedly, and his plasma lactate concentration 
was maintained at nearly normal levels. No adverse effects 
of this therapy have been observed, and at 5 years of age 
his cognitive functions were age appropriate, whereas 
his motor development was moderately impaired. The rea­
son for this favorable outcome is unclear, DCA is effective 
in lowering plasma lactate levels, but its administration has 
not been associated with improvement of preexisting 
neurologic damage.11 Our patient had only mild neurolo­
gic impairment when therapy was initiated. In view of the 
normal level of cerebrospinal fluid lactate and the normal 
results on neuroimaging and neurophysiologic studies, the 
possibility of a high residual LAD activity in the central 
nervous system cannot be excluded. We speculate that the 
main contribution of this therapy was preventive, by reduc­
ing the frequency and severity of the decompensation epi­
sodes. In previously described patients with LAD defi­
ciency, such events worsened preexisting neurologic dam­
age.4, 5
We conclude that DCA administration may be of benefit 
in children with LAD deficiency for the control of plasma 
lactate values and the attenuation of frequency and sever­
ity of decompensation episodes.
We acknowledge most helpful discussions with Prof. C. Bach- 
mann, Switzerland, and the expert technical assistance of E. Chen.
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